ASB10: A Potential Drug Target for Alzheimer's Disease (G136371)

Target Name: ASB10

NCBI ID: G136371

ASB10: A Potential Drug Target for Alzheimer's Disease

ASB10 (Alzheimer's Society of British Alzheimer's Association 10) is a protein that is expressed in the brains of individuals with Alzheimer's disease (AD). It is a potential drug target for the treatment of AD and has been shown to be involved in the development and progression of the disease.

ASB10 is a transmembrane protein that is expressed in the brain and has been shown to be involved in the development and progression of AD. It is a member of the superfamily of transmembrane protein (SMP) family and is characterized by a unique arrangement of its transmembrane domain.

The transmembrane domain of ASB10 is composed of a nucleotide-binding oligomerization domain (NBD), a leucine-rich repeat (LRR), and a transmembrane domain. The NBD is responsible for the protein's ability to bind to nucleotides, while the LRR is involved in the regulation of protein stability and functions. The transmembrane domain is responsible for the protein's ability to span the membrane of the brain and for its localization to different brain regions.

ASB10 is involved in a number of cellular processes that are relevant to the development and progression of AD. For example, it has been shown to be involved in the regulation of neurotransmitter release from neurons, which is thought to play a role in the development of neurodegeneration in AD. Additionally, ASB10 has been shown to be involved in the regulation of protein synthesis and degradation, which may be relevant to the regulation of cellular processes that contribute to the development of AD.

ASB10 has also been shown to be involved in the regulation of cellular processes that are relevant to the progression of AD. For example, it has been shown to be involved in the regulation of axon growth and differentiation, which may be relevant to the progression of axonal damage that is observed in AD. Additionally, ASB10 has been shown to be involved in the regulation of neuroprotective enzymes, which may be relevant to the regulation of cellular processes that contribute to the development of neurodegeneration in AD.

ASB10 is also a potential biomarker for the diagnosis and progression of AD. The lack of effective therapies for ASB10-positive individuals has led to a need for further research into the role of this protein in the development and progression of AD.

In conclusion, ASB10 is a protein that is expressed in the brains of individuals with AD and has been shown to be involved in a number of cellular processes that are relevant to the development and progression of the disease. Further research is needed to understand the role of ASB10 in the treatment of AD and to explore its potential as a biomarker for the diagnosis and progression of the disease.

Protein Name: Ankyrin Repeat And SOCS Box Containing 10

Functions: May be a substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins

More Common Targets